

# Market Announcement

8 July 2022

---

## Lumos Diagnostics Holdings Limited (ASX: LDX) – Suspension from Quotation

### Description

The securities of Lumos Diagnostics Holdings Limited ('LDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of LDX, pending the release of an announcement regarding a response to regulatory feedback received in relation to FebriDx.

### Issued by

**Alice Montefiore-King**  
Adviser, Listings Compliance (Sydney)



8 July 2022

Alice Montefiore-King  
Adviser, Listings Compliance (Sydney)  
ASX Compliance Pty Limited  
20 Bridge Street  
Sydney NSW 2000

**By email only:** [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

Dear Alice,

**REQUEST FOR VOLUNTARY SUSPENSION**

Lumos Diagnostics Holdings Limited (ASX: LDX) (the Company) requests a voluntary suspension of the Company's securities (ASX: LDX) quoted on the Australian Securities Exchange (**ASX**) effective immediately.

In accordance with ASX Listing Rule 17.2, the Company provides the following information in relation to the request:

1. The voluntary suspension is necessary to allow the Company to prepare a full response to regulatory feedback received in relation to FebriDx.
2. The Company anticipates that the voluntary suspension will remain in place until the earlier of the commencement of normal trading on Monday, 11 July 2022 or when the anticipated announcement is released to the market
3. The Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Tracy Weimar", with a long horizontal flourish extending to the right.

Tracy Weimar  
Company Secretary  
**Lumos Diagnostics Holdings Limited**